KZR 18,33$

https://old.nasdaq.com/de/symbol/kzr/real-time  

 

https://old.nasdaq.com/de/symbol/kzr/real-time  

6,27USD

+0,26USD

+4,33%  

We currently estimate that our cash, cash equivalents and marketable securities as of March 31, 2020 will be sufficient to fund our operations into the thirdquarter of 2022. (Seite 18)

http://investors.kezarlifesciences.com/...d28b-4897-8a91-2c86f1aa4ee2

Sind sowieso ein paar schöne Passagen dabei:
Additionally, we are advancing our novel research platform targeting the Sec61 translocon and the protein secretion pathway to discover and develop smallmolecule therapeutics targeting oncology indications. Our first clinical candidate in this program, KZR-261, has demonstrated broad anti-tumor activity inpreclinical models of both solid and hematologic malignancies. KZR-261 is undergoing laboratory studies and manufacturing activities in support of aninvestigational new drug, or IND, application, which we anticipate submitting to the U.S. Food and Drug Administration, or FDA, in the first quarter of2021 for a Phase 1 clinical trial in solid tumors. We believe this discovery platform has the potential to yield oral small molecule candidates that, ifsuccessfully developed and approved, could serve as alternatives to currently marketed biologic therapeutics to act as cytotoxic anti-cancer agents or toblock the secretion of novel targets of interest in immuno-oncology or inflammation.

 

KZR-616 is under a phase Ib/II study in systemic lupus erythematosus patients with and without nephritis, dubbed MISSION. In the study, KZR-616 is administered as a subcutaneous injection weekly for 13 weeks or 24 weeks.

https://www.rttnews.com/3101074/...ces-smartsheet-cloudera-zuora.aspx
 

http://investors.kezarlifesciences.com/...pdate-mission-study-kzr-616  

https://old.nasdaq.com/de/symbol/kzr/real-time  

KZR-616 is a immunoproteasome inhibitor that the company says delivers a broad anti-inflammatory response and has shown potential efficacy in reducing the severity of certain autoimmune diseases (e.g., lupus, rheumatoid arthritis, IBD, MS, type 1 diabetes) in animal models.


https://seekingalpha.com/news/...eed_news_all&utm_medium=referral  

Gerne!

Kezar Life Sciences (KZR)

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Kezar Life Sciences, with a price target of $12.00. The company’s shares closed last Wednesday at $4.47.

According to TipRanks.com, Selvaraju is a top 100 analyst with an average return of 25.6% and a 60.1% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Taro Pharmaceutical Industries, Turning Point Therapeutics, and Black Diamond Therapeutics.

https://www.analystratings.com/articles/...o-kezar-life-sciences-kzr/  

im Gegenteil, wenn`s noch was etwas tiefer geht stocke ich hier noch mal auf! Sehe auch die Amis wohl so. Wenn ich das Volumen von gestern und heute vergleiche. Die haben Cash ohne Ende, also bis Ende 2022 :) und da geht noch Einiges. Zudem ging es gestern teilweise über 100 Prozent hoch und ich fand die Nachricht jetzt nicht so spektakulär. Da lass hier erstmal ne richtig starke Nachricht kommen...und wie gestern schon geschrieben hat der Wirkstoff wohl einiges an Potential so wie eben die Aktie auch.  

nächstes Offering im Anmarsch

http://investors.kezarlifesciences.com/...ublic-offering-common-stock

 

da kann ich nur mit dem Kopf schütteln :(  

47 Mio. $ Offering

" Kezar Life Sciences, Inc. a clinical-stage biotechnology company discovering and developing novel small molecule therapeutics to treat unmet needs in autoimmune disease and cancer, today announced the pricing of an underwritten public offering of 7,590,909 shares of its common stock, and to certain investors in lieu thereof, pre-funded warrants to purchase 909,091 shares of its common stock at an exercise price of $0.001 per share. The public offering price of each share of common stock is $5.50 and the public offering price of each pre-funded warrant is $5.499 per underlying share. In addition, Kezar has granted the underwriters a 30-day option to purchase up to an additional 1,275,000 shares of common stock. The offering is expected to close on June 11, 2020, subject to customary closing conditions."

http://investors.kezarlifesciences.com/...ng-467-million-common-stock

 

https://old.nasdaq.com/de/symbol/kzr/real-time  

Damit hat die Aktie von KZR alle Gewinne wieder abgegeben, die sie durch die letzten News erzielt hatte.

 

https://old.nasdaq.com/de/symbol/kzr/real-time  

https://old.nasdaq.com/de/symbol/kzr/premarket  

Phase1b Studiendaten von KZR-616 (in Lupus)

https://investors.kezarlifesciences.com/...-mission-phase-1b-study-of

https://seekingalpha.com/news/...kezar-life-sciences-up-9-after-hours

 

Zahlen für Q3/20

• keine Umsatz
  
• Verlust 11 Mio. $
  
• Cash 150 Mio. $
  
• MK 250 Mio. $
  
• KZR-261 IND submission on-track for Q1 2021
  

https://www.kezarlifesciences.com/investors/...quarter-2020-financial

 

https://www.finanznachrichten.de/...ktien/kezar-life-sciences-inc.htm  

 

 

Da sollte auch die nächsten Wochen was kommen!